MASLD Liver Fibrosis: How to Detect, Stage and Treat It Before Cirrhosis Strikes

Metabolic dysfunction-associated steatotic liver disease (MASLD)—the 2023 successor term to NAFLD—is now the world's most prevalent chronic liver disease, affecting more than 30% of adults globally. Its diagnosis requires hepatic steatosis plus at least one cardiometabolic risk factor (obesity, hypertension, dysglycaemia, or dyslipidaemia) while excluding significant alcohol use. This comprehensive 2026 narrative review from an international team (Charité Berlin and First Hospital of Jilin University) synthesises the epidemiology, fibrosis biology, non-invasive diagnostics, and rapidly evolving pharmacotherapy of MASLD-related fibrosis.

Fibrosis severity—not steatosis or even steatohepatitis alone—is the paramount determinant of patient outcomes. In a prospective cohort of 1,773 MASLD adults, all-cause mortality reached 0.89 per 100 person-years at F3 and 1.76 per 100 person-years at F4 (cirrhosis). Among MASH patients, 25–33% experience fibrosis progression and 5–15% progress to cirrhosis over time; 2–5% ultimately develop hepatocellular carcinoma (HCC). Importantly, MASLD-related HCC increasingly arises in non-cirrhotic livers, arguing for surveillance in high-risk patients with moderate-to-advanced fibrosis. Cardiovascular disease remains the leading cause of death in non-cirrhotic MASLD, underscoring the need for holistic cardiometabolic risk management.

A structured, stepwise non-invasive testing (NIT) algorithm is central to the review. FIB-4 (using age, AST, ALT, and platelets) serves as the preferred first-line screen; scores above 1.3 (or 2.0 in those over 65) trigger secondary assessment with the ELF test or elastography. Vibration-controlled transient elastography (VCTE/FibroScan) is the preferred second-line tool for ruling in advanced fibrosis, while MR elastography offers the highest accuracy for specialist settings. Next-generation biomarkers—PRO-C3, the ADAPT score (achieving 92.5% diagnostic accuracy in serial use), and metabolomics-based indices like the MASEF score—are positioned as near-clinical or investigational tools that may better capture active fibrogenesis.

The pharmacotherapy landscape has transformed following the FDA approval of resmetirom (a thyroid hormone receptor-β agonist) for MASH with significant fibrosis. The review organises therapeutic agents by mechanism: (1) incretin-based agents—GLP-1 receptor agonists (semaglutide), dual GLP-1/GIP agonists (tirzepatide), and triple GLP-1/GIP/glucagon agonists—address metabolic stress and promote weight loss; (2) hepatocyte-directed metabolic modulators including THR-β agonists, fatty acid synthase (FASN) inhibitors, and acetyl-CoA carboxylase (ACC) inhibitors target de novo lipogenesis; (3) bile acid pathway therapies via FXR agonists (obeticholic acid, tropifexor) modulate inflammation and fibrogenesis; (4) FGF21 analogues (pegbelfermin, efruxifermin) and PPAR agonists (lanifibranor) act as pleiotropic metabolic-fibrotic regulators. Combination regimens pairing agents with complementary mechanisms are identified as the most promising frontier. Genetic risk stratification (e.g., PNPLA3, TM6SF2 variants) and hepatocyte-targeted oligonucleotide therapies (siRNA, ASO) represent emerging precision approaches.

The review acknowledges that surrogate histological endpoints (MASH resolution without fibrosis worsening; fibrosis improvement by ≥1 stage) remain the basis for regulatory approval, with ongoing debate about whether non-invasive biomarker changes can substitute in future trials. Lifestyle modification and sustained ≥7–10% body weight loss remain the foundation of care for all fibrosis stages. The authors advocate for stage-specific, mechanism-informed combination regimens and propose that future trials should integrate genetic stratification and validated non-invasive endpoints to accelerate drug development and enable personalised therapy.